MODIFIED ANTIBODIES AND METHODS OF USE
Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly useful for the treatment of neoplastic disorders in myelosuppressed patients.
1 . A domain deleted CC49 antibody reactive with TAG-72 comprising a heavy chain having an amino acid sequence substantially as set forth in FIG. 4A .
2 . The domain deleted CC49 antibody of claim 1 further comprising a cytotoxic agent.
3 . The domain deleted CC49 antibody of claim 2 wherein said cytotoxic agent is a radionuclide.
4 - 5 . (canceled)
6 . The domain deleted CC49 antibody of claim 1 further comprising an amino acid spacer.
7 . The a domain deleted CC49 antibody of claim 1 , having a heavy chain amino acid sequence substantially as set forth in FIG. 4A covalently linked to one or more bifunctional chelators wherein said one or more bifunctional chelators is associated with 90Y.
8 . The domain deleted CC49 antibody of claim 7 wherein said bifunctional chelator is selected from the group consisting of MX-DTPA and CHX-DTPA.
9 . A domain deleted C2B8 antibody reactive with CD20 comprising a heavy chain having an amino acid sequence substantially as set forth in FIG. 1B .
10 . The domain deleted C2B8 antibody of claim 9 further comprising a cytotoxic agent.
11 . The domain deleted C2B8 antibody of claim 10 wherein said cytotoxic agent is a radionuclide.
12 .- 13 . (canceled)
14 . A method of imaging a neoplasm comprising a tumor associated antigen in a patient in need thereof comprising the steps of: administering a modified antibody to said patient wherein said modified antibody is associated with an imaging agent and binds to said tumor associated antigen; and imaging said patient to reveal said neoplasm.
15 . The method of claim 14 wherein said imaging agent is a radioisotope.
16 . The method of claim 15 wherein said radioisotope is associated with said modified antibody via a bifunctional chelator.
17 . (canceled)
18 . A method of treating a patient suffering from a neoplastic disorder comprising the step of administering a therapeutically effective amount of a modified antibody to said patient.
19 . The method of claim 18 wherein said modified antibody comprises a domain deleted antibody.
20 . (canceled)
21 . The method of claim 19 wherein said domain deleted antibody comprises an amino acid spacer.
22 . The method of claim 18 wherein said modified antibody reacts with a tumor associated antigen.
23 - 25 . (canceled)
26 . The method of claim 18 wherein said modified antibody is associated with a cytotoxic agent.
27 . The method of claim 26 wherein said cytotoxic agent comprises a radioisotope.
28 - 29 . (canceled)
30 . The method of claim 18 wherein said neoplastic disorder is a hematologic neoplasm.
31 . The method of claim 18 wherein said myelosuppressed patient exhibits an ANC of less than about 1500/mm3.
32 . The method of claim 31 wherein said myelosuppressed patient has a white cell count of less than about 1000/mm3.
33 . A method of treating a patient exhibiting a neoplastic disorder comprising the steps of: administering a therapeutically effective amount of at least one chemotherapeutic agent to said patient; and administering a therapeutically effective amount of at least one modified antibody to said patient wherein said chemotherapeutic agent and said modified antibody may be administered in any order or concurrently.
34 . The method of claim 33 wherein said modified antibody comprises a domain deleted antibody.
35 . (canceled)
36 . The method of claim 33 wherein said domain deleted antibody comprises a spacer.
37 . The method of claim 33 wherein said modified antibody reacts with a tumor associated antigen.
38 - 40 . (canceled)
41 . The method of claim 33 wherein said modified antibody is associated with a cytotoxic agent.
42 . The method of claim 41 wherein said cytotoxic agent comprises a radioisotope.
43 - 44 . (canceled)
45 . The method of claim 33 wherein said neoplastic disorder is a hematologic neoplasm.
46 . The method of claim 33 wherein said patient has a white cell count of less than about 1500/mm3.
47 . The method of claim 33 wherein said patient has a white cell count of less than about 1000/mm3.
48 . The method of claim 33 wherein said chemotherapeutic agent is administered prior to said modified antibody.
49 . The method of claim 48 wherein said modified antibody is administered within a month of said chemotherapeutic agent.
50 . The method of claim 48 wherein said modified antibody is administered within two weeks of said chemotherapeutic agent.
51 - 60 . (canceled)
61 . The method of claim 18 wherein the patient is myelosuppressed.
62 . The method of claim 18 wherein the patient is currently undergoing a course of chemotherapy.
63 . The method of claim 18 wherein the patient is a relapsed patient.
64 . The method of claim 18 wherein neoplasm is color coded.
65 . The method of claim 18 wherein modified antibody is selected from the group consisting of CC49.ΔCH2 AND C2B8.ΔCH2.